129 related articles for article (PubMed ID: 25329832)
1. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
[TBL] [Abstract][Full Text] [Related]
2. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
3. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
[TBL] [Abstract][Full Text] [Related]
4. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
[TBL] [Abstract][Full Text] [Related]
5. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
[TBL] [Abstract][Full Text] [Related]
6. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Functional Characterization of α Chain of Interleukin-15 Receptor (
Zhang Y; Wu F; Yang G; Jian J; Lu Y; Wang Z
Animals (Basel); 2023 Nov; 13(23):. PubMed ID: 38066992
[TBL] [Abstract][Full Text] [Related]
8. Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines
Shehata HM; Dogra P; Gierke S; Holder P; Sanjabi S
Front Immunol; 2024; 15():1341804. PubMed ID: 38515757
[TBL] [Abstract][Full Text] [Related]
9. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.
Saeed MA; Peng B; Kim K; Rawat K; Kuehm LM; Siegel ZR; Borkowski A; Habib N; Van Tine B; Sheikh N; Tuyen V; Thorek DLJ; Fehniger TA; Pachynski RK
Cancer Immunol Res; 2024 May; 12(5):559-574. PubMed ID: 38407894
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Zymosan Treatment Induces IL15-Secreting Macrophages and KLRG1-Expressing NK Cells in Mice.
Park HJ; Lee SW; Park YH; Kim TC; Lee S; Lee S; Van Kaer L; Hong S
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570749
[TBL] [Abstract][Full Text] [Related]
11. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.
Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501
[TBL] [Abstract][Full Text] [Related]
12. IL15 and IL21: Better When Membrane-Tethered Together on Antitumor T Cells.
Ruffin AT; Wittling MC; Cole AC; Paulos CM
Clin Cancer Res; 2024 Apr; 30(8):1431-1433. PubMed ID: 38289325
[TBL] [Abstract][Full Text] [Related]
13. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
[TBL] [Abstract][Full Text] [Related]
14. Changing the peptide specificity of a human T-cell receptor by directed evolution.
Smith SN; Wang Y; Baylon JL; Singh NK; Baker BM; Tajkhorshid E; Kranz DM
Nat Commun; 2014 Nov; 5():5223. PubMed ID: 25376839
[TBL] [Abstract][Full Text] [Related]
15. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
16. CAR-NK cell therapy for glioblastoma: what to do next?
Xiong Q; Zhu J; Zhang Y; Deng H
Front Oncol; 2023; 13():1192128. PubMed ID: 37404752
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
Kardani K; Sanchez Gil J; Rabkin SD
Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
[TBL] [Abstract][Full Text] [Related]
18. Research progress of interleukin-15 in cancer immunotherapy.
Cai M; Huang X; Huang X; Ju D; Zhu YZ; Ye L
Front Pharmacol; 2023; 14():1184703. PubMed ID: 37251333
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
